Capecitabine in Combination with Docetaxel in First Line in HER2-Negative Metastatic Breast Cancer: an Observational Study

Overview

Journal Pathol Oncol Res

Specialty Oncology

Date 2016 Oct 25

PMID 27771885

Authors

Renata Koszo

Dora Santha

Laszlo Budi

Jozsef Erfan

Karoly Gyorfy

Zsolt Horvath

Judit Kocsis

Laszlo Landherr

Erika Hitre

Karoly Mahr

Gabor Pajkos

Zsuzsanna Papai

Zsuzsanna Kahan

Affiliations

Soon will be listed here.

Abstract

Due to the limited experience with capecitabine plus docetaxel (XT) combination in the first-line treatment of metastatic breast cancer in Hungary, the main objective of the study was to analyze the effectiveness and tolerability of XT therapy. A prospective, open-label, non-randomized, single-arm, multicenter, observational study was designed. All female patients were eligible whose metastatic breast cancer could be treated with the XT protocol according to the summary of product characteristics of the drugs. The median progression free survival was 9.9 ± 3.0 months. Time to treatment failure was 4.6 ± 5.1 months on average. The overall response rate was 28.9 %, the clinical benefit rate was 73.3 %. The treatment was discontinued in 35.6 % of patients due to disease progression and in 20.0 % due to adverse events (AE). 33 patients with a total of 73 AEs have been reported, and 13 of them had serious adverse events (SAE). The efficacy and the safety profile of XT chemotherapy proven in the study are consistent with the results demonstrated in randomized trials. First-line XT chemotherapy effectively improves the PFS in metastatic breast cancer.

References

Budman D, Meropol N, Reigner B, Creaven P, Lichtman S, Berghorn E . Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J Clin Oncol. 1998; 16(5):1795-802. DOI: 10.1200/JCO.1998.16.5.1795. View

Rich T, Shepard R, Mosley S . Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol. 2004; 22(11):2214-32. DOI: 10.1200/JCO.2004.08.009. View

Bachelot T, Bajard A, Ray-Coquard I, Provencal J, Coeffic D, Agostini C . Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer. Oncology. 2011; 80(3-4):262-8. DOI: 10.1159/000329066. View

Buzdar A, Xu B, Digumarti R, Goedhals L, Hu X, Semiglazov V . Randomized phase II non-inferiority study (NO16853) of two different doses of capecitabine in combination with docetaxel for locally advanced/metastatic breast cancer. Ann Oncol. 2011; 23(3):589-597. DOI: 10.1093/annonc/mdr256. View

Milano G, Etienne M, Renee N, Thyss A, Schneider M, Ramaioli A . Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol. 1994; 12(6):1291-5. DOI: 10.1200/JCO.1994.12.6.1291. View

Yu J, DI L, Song G, Che L, Jiang H, Zhu Y . [Randomized clinical case-control trial for the comparison of docetaxel plus thiotepa versus docetaxel plus capecitabine in patients with metastatic breast cancer]. Beijing Da Xue Xue Bao Yi Xue Ban. 2011; 43(1):151-6. View

Pronk L, Vasey P, Sparreboom A, Reigner B, Planting A, Gordon R . A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer. 2000; 83(1):22-9. PMC: 2374547. DOI: 10.1054/bjoc.2000.1160. View

Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K . Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998; 34(8):1274-81. DOI: 10.1016/s0959-8049(98)00058-6. View

Seidman A, Brufsky A, Ansari R, Hart L, Stein R, Schwartzberg L . Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Ann Oncol. 2010; 22(5):1094-1101. DOI: 10.1093/annonc/mdq578. View

10.

Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N . Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann Oncol. 2009; 21(1):48-54. DOI: 10.1093/annonc/mdp498. View

11.

Chan S, Romieu G, Huober J, Delozier T, Tubiana-Hulin M, Schneeweiss A . Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol. 2009; 27(11):1753-60. DOI: 10.1200/JCO.2007.15.8485. View

12.

Blum J, Dees E, Chacko A, Doane L, Ethirajan S, Hopkins J . Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2006; 24(27):4384-90. DOI: 10.1200/JCO.2005.05.1383. View

13.

Michalaki V, Gennatas S, Gennatas K . Low-dose capecitabine plus docetaxel as first-line therapy for metastatic breast cancer: phase II results. Anticancer Drugs. 2009; 20(3):204-7. DOI: 10.1097/CAD.0b013e328327d492. View

14.

Lockshin A, Danenberg P . Biochemical factors affecting the tightness of 5-fluorodeoxyuridylate binding to human thymidylate synthetase. Biochem Pharmacol. 1981; 30(3):247-57. DOI: 10.1016/0006-2952(81)90085-x. View

15.

Vici P, Giotta F, Di Lauro L, Sergi D, Vizza E, Mariani L . A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study. Oncology. 2011; 81(3-4):230-6. DOI: 10.1159/000334432. View

16.

Harvey V, Mouridsen H, Semiglazov V, Jakobsen E, Voznyi E, Robinson B . Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol. 2006; 24(31):4963-70. DOI: 10.1200/JCO.2005.05.0294. View

17.

Gradishar W, Meza L, Amin B, Samid D, Hill T, Chen Y . Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol. 2004; 22(12):2321-7. DOI: 10.1200/JCO.2004.12.128. View

18.

Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H . Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998; 4(4):1013-9. View

19.

OShaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub J, Cervantes G . Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002; 20(12):2812-23. DOI: 10.1200/JCO.2002.09.002. View

20.

Liang X, Yan Y, Wang L, Song G, Di L, Jiang H . First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. Oncol Lett. 2015; 9(2):987-993. PMC: 4301516. DOI: 10.3892/ol.2014.2787. View